Individualized Cost-Effectiveness Analysis

1. GoldMRSiegelJERussellLBWeinsteinMC 1996 Cost-effectiveness in health and medicine Oxford Oxford University Press

2. WillanAR 2001 On the probability of cost-effectiveness using data from randomized clinical trials. BMC Med Res Methodol 1 8

3. O'HaganAStevensJW 2002 The probability of cost-effectiveness. BMC Med Res Methodol 2 5

4. KravitzRLDuanNBraslowJ 2004 Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 82 661 687

5. McLaughlinMJ HTE Policy Roundtable Panel 2007 Healthcare policy implications of heterogeneity of treatment effects. Am J Med 120 4Suppl 1 S32 S35

6. GreenfieldSKravitzRDuanNKaplanSH 2007 Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 120 4Suppl 1 S3 S9

7. GlasziouPPIrwigLM 1995 An evidence based approach to individualising treatment. BMJ 311 1356 1359

8. GarberAM 2000 Advances in cost-effectiveness analysis of health interventions. CulyerAJNewhouseJP Handbook of health economics, Volume 1 Amsterdam North-Holland 181 221

9. MendeloffJKoKRobertsMSByrneMDewMA 2004 Procuring organ donors as a health investment: how much should we be willing to spend? Transplanation 78 1704 1710

10. HermanWHHoergerTJBrandleMHicksKSorensenS 2005 The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142 323 332

11. LuceR 2000 Utility of gains and losses: measurement-theoretical and experimental approaches Mahwah (New Jersey) Lawrence Erlbaum Associates

12. ByrnesJPMillerDCSchaferWD 1999 Gender differences in risk taking: A meta-analysis. Psych Bull 125 367 383

13. ElbashaEH 2005 Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Econ 14 457 470

14. SapienzaPZingalesLMaestripieriD 2009 Gender differences in financial risk aversion and career choices are affected by testosterone. Proc Natl Acad Sci U S A 106 15268 15273

15. FinckhABansbackNMarraCAAnisAHMichaudK 2009 Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 151 612 621

16. EckmanMHRosandJGreenbergSMGageBF 2009 Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150 73 83

17. PletcherMJLazarLBibbins-domingoKMoranARodondiN 2009 Comparing impact and cost-effectiveness of primary prevention strategies for lipid lowering. Ann Intern Med 150 243 254

18. PauldenMPalmerSHewittCGilbodyS 2009 Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ 339 b5203 doi:10.1136/bmj.b5203

19. LatimerNLordJGrantRLO'MahonyRDicksonJ 2009 Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 339 b2538 doi:10.1136/bmj.b2538

20. EpsteinDBojkeLSculpherMJ REFLUX Trial Group 2009 Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ 339 b2576 doi:10.1136/bmj.b2576

21. RoseJHawthornRLWattsBSingerME 2009 Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 339 b3653 doi:10.1136/bmj.b3653

22. BartonGRSachTHJenkinsonCDohertyMAveryAJ 2009 Lifestyle interventions for knee pain in overweight and obese adults aged > or  = 45: economic evaluation of randomised controlled trial. BMJ 339 b2273

23. LaskaEMMeisnerMSiegelC 1997 Statistical inference for cost-effectiveness ratios. Health Econ 6 229 242

24. BriggsAFennP 1997 Trying to do better than average: a commentary on ‘statistical inference for cost-effectiveness ratios’. Health Econ 6 491 495

25. IoannidisJPLauJ 1997 The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol 50 1089 1098

26. KentDMRothwellPMIoannidisJPAltmanDGHaywardRA 2010 Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials 11 85

27. MarkDBHlatkyMACaliffRMNaylorCDLeeKL 1995 Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 332 1418 1424

28. GilbodySWilsonPWattI 2005 Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care 14 246 250

29. WrightCFHallAZimmernRL 2011 Regulating direct-to-consumer genetic tests: What is all the fuss about? Genet Med 13 295 300

30. CohenJPPaquetteCCairnsCP 2005 Switching prescription drugs to over the counter. BMJ 330 39 41

31. NeaseRFJrOwensDK 1994 A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making 14 382 392

32. GageBFCardinalliABOwensDK 1998 Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29 1083 1091

33. GafniABirchSMehrezA 1993 Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year). J Health Econ 12 325 339

34. MehrezAGafniA 1989 Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 9 142 149

35. MehrezAGafniA 1991 The healthy-years equivalents: how to measure them using the standard gamble approach. 11 140 146

36. HutchingsADurandMAGrieveRHarrisonDRowanK 2009 Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis. BMJ 339 b4353 doi:10.1136/bmj.b4353

37. KimJJGoldieSJ 2009 Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339 b3884 doi:10.1136/bmj.b3884

38. KhazeniNHuttonDWGarberAMHupertNOwensDK 2009 Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 151 829 839

39. BellCMUrbachDRRayJGBayoumiARosenAB 2006 Bias in published cost effectiveness studies: systematic review. BMJ 332 699 703

40. MinersAHGarauMFidanDFischerAJ 2005 Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ 330 65

41. PolyzosNPValachisAMauriDIoannidisJPA 2011 Sponsorship bias in assumptions of cost-effectiveness analysis: the diagnostic accuracy of the Pap test. CMAJ In press

42. HochJSDewaCS 2007 Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 25 807 816

43. O'BrienBJSculpherMJ 2000 Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. Med Care 38 460 468

44. OwensDKQaseemAChouRShekelleP Clinical Guidelines Committee of the American College of Physicians 2011 High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 154 174 180